Selected research
Market Structure
Global Equine Rhinopneumonitis Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Equine Rhinopneumonitis Vaccine market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Equine Rhinopneumonitis Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Equine Rhinopneumonitis Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Equine Rhinopneumonitis Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Equine Rhinopneumonitis Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Equine Rhinopneumonitis Vaccine include Merck, Zoetis, Santa Cruz Animal Health, Nisseiken Co., Ltd. and Boehringer Ingelheim, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Equine Rhinopneumonitis Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Equine Rhinopneumonitis Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Equine Rhinopneumonitis Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Equine Rhinopneumonitis Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.
Equine Rhinopneumonitis Vaccine Segment by Company
Merck
Zoetis
Santa Cruz Animal Health
Nisseiken Co., Ltd.
Boehringer Ingelheim
Equine Rhinopneumonitis Vaccine Segment by Type
Live
Inactivated
Equine Rhinopneumonitis Vaccine Segment by Application
Veterinary Pharmacy
Online Sale
Others
Equine Rhinopneumonitis Vaccine Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Equine Rhinopneumonitis Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Equine Rhinopneumonitis Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Equine Rhinopneumonitis Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Equine Rhinopneumonitis Vaccine market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Equine Rhinopneumonitis Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Equine Rhinopneumonitis Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Equine Rhinopneumonitis Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Live
- Inactivated
Applications
- Veterinary Pharmacy
- Online Sale
- Others
Companies covered
- Merck
- Zoetis
- Santa Cruz Animal Health
- Nisseiken Co., Ltd.
- Boehringer Ingelheim
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Equine Rhinopneumonitis Vaccine Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Equine Rhinopneumonitis Vaccine Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Equine Rhinopneumonitis Vaccine Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Equine Rhinopneumonitis Vaccine Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Equine Rhinopneumonitis Vaccine Market Dynamics
- 2.1 Equine Rhinopneumonitis Vaccine Industry Trends
- 2.2 Equine Rhinopneumonitis Vaccine Industry Drivers
- 2.3 Equine Rhinopneumonitis Vaccine Industry Opportunities and Challenges
- 2.4 Equine Rhinopneumonitis Vaccine Industry Restraints
3 Equine Rhinopneumonitis Vaccine Market by Manufacturers
- 3.1 Global Equine Rhinopneumonitis Vaccine Revenue by Manufacturers (2021-2026)
- 3.2 Global Equine Rhinopneumonitis Vaccine Sales by Manufacturers (2021-2026)
- 3.3 Global Equine Rhinopneumonitis Vaccine Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Equine Rhinopneumonitis Vaccine Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Equine Rhinopneumonitis Vaccine Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Equine Rhinopneumonitis Vaccine Manufacturers, Product Type & Application
- 3.7 Global Equine Rhinopneumonitis Vaccine Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Equine Rhinopneumonitis Vaccine Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Equine Rhinopneumonitis Vaccine Players Market Share by Revenue in 2025
- 3.8.3 2025 Equine Rhinopneumonitis Vaccine Tier 1, Tier 2, and Tier 3
4 Equine Rhinopneumonitis Vaccine Market by Type
- 4.1 Equine Rhinopneumonitis Vaccine Type Introduction
- 4.1.1 Live
- 4.1.2 Inactivated
- 4.2 Global Equine Rhinopneumonitis Vaccine Sales by Type
- 4.2.1 Global Equine Rhinopneumonitis Vaccine Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Equine Rhinopneumonitis Vaccine Sales by Type (2021-2032)
- 4.2.3 Global Equine Rhinopneumonitis Vaccine Sales Market Share by Type (2021-2032)
- 4.3 Global Equine Rhinopneumonitis Vaccine Revenue by Type
- 4.3.1 Global Equine Rhinopneumonitis Vaccine Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Equine Rhinopneumonitis Vaccine Revenue by Type (2021-2032)
- 4.3.3 Global Equine Rhinopneumonitis Vaccine Revenue Market Share by Type (2021-2032)
5 Equine Rhinopneumonitis Vaccine Market by Application
- 5.1 Equine Rhinopneumonitis Vaccine Application Introduction
- 5.1.1 Veterinary Pharmacy
- 5.1.2 Online Sale
- 5.1.3 Others
- 5.2 Global Equine Rhinopneumonitis Vaccine Sales by Application
- 5.2.1 Global Equine Rhinopneumonitis Vaccine Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Equine Rhinopneumonitis Vaccine Sales by Application (2021-2032)
- 5.2.3 Global Equine Rhinopneumonitis Vaccine Sales Market Share by Application (2021-2032)
- 5.3 Global Equine Rhinopneumonitis Vaccine Revenue by Application
- 5.3.1 Global Equine Rhinopneumonitis Vaccine Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Equine Rhinopneumonitis Vaccine Revenue by Application (2021-2032)
- 5.3.3 Global Equine Rhinopneumonitis Vaccine Revenue Market Share by Application (2021-2032)
6 Global Equine Rhinopneumonitis Vaccine Sales by Region
- 6.1 Global Equine Rhinopneumonitis Vaccine Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Equine Rhinopneumonitis Vaccine Sales by Region (2021-2032)
- 6.2.1 Global Equine Rhinopneumonitis Vaccine Sales by Region (2021-2026)
- 6.2.2 Global Equine Rhinopneumonitis Vaccine Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Equine Rhinopneumonitis Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Equine Rhinopneumonitis Vaccine Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Equine Rhinopneumonitis Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Equine Rhinopneumonitis Vaccine Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Equine Rhinopneumonitis Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Equine Rhinopneumonitis Vaccine Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Equine Rhinopneumonitis Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Equine Rhinopneumonitis Vaccine Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Equine Rhinopneumonitis Vaccine Revenue by Region
- 7.1 Global Equine Rhinopneumonitis Vaccine Revenue by Region
- 7.1.1 Global Equine Rhinopneumonitis Vaccine Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Equine Rhinopneumonitis Vaccine Revenue by Region (2021-2026)
- 7.1.3 Global Equine Rhinopneumonitis Vaccine Revenue by Region (2027-2032)
- 7.1.4 Global Equine Rhinopneumonitis Vaccine Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Equine Rhinopneumonitis Vaccine Revenue (2021-2032)
- 7.2.2 North America Equine Rhinopneumonitis Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Equine Rhinopneumonitis Vaccine Revenue (2021-2032)
- 7.3.2 Europe Equine Rhinopneumonitis Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Equine Rhinopneumonitis Vaccine Revenue (2021-2032)
- 7.4.2 Asia-Pacific Equine Rhinopneumonitis Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Equine Rhinopneumonitis Vaccine Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Equine Rhinopneumonitis Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Merck
- 8.1.1 Merck Company Information
- 8.1.2 Merck Business Overview
- 8.1.3 Merck Equine Rhinopneumonitis Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Merck Equine Rhinopneumonitis Vaccine Product Portfolio
- 8.1.5 Merck Recent Developments
- 8.2 Zoetis
- 8.2.1 Zoetis Company Information
- 8.2.2 Zoetis Business Overview
- 8.2.3 Zoetis Equine Rhinopneumonitis Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Zoetis Equine Rhinopneumonitis Vaccine Product Portfolio
- 8.2.5 Zoetis Recent Developments
- 8.3 Santa Cruz Animal Health
- 8.3.1 Santa Cruz Animal Health Company Information
- 8.3.2 Santa Cruz Animal Health Business Overview
- 8.3.3 Santa Cruz Animal Health Equine Rhinopneumonitis Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Santa Cruz Animal Health Equine Rhinopneumonitis Vaccine Product Portfolio
- 8.3.5 Santa Cruz Animal Health Recent Developments
- 8.4 Nisseiken Co., Ltd.
- 8.4.1 Nisseiken Co., Ltd. Company Information
- 8.4.2 Nisseiken Co., Ltd. Business Overview
- 8.4.3 Nisseiken Co., Ltd. Equine Rhinopneumonitis Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Nisseiken Co., Ltd. Equine Rhinopneumonitis Vaccine Product Portfolio
- 8.4.5 Nisseiken Co., Ltd. Recent Developments
- 8.5 Boehringer Ingelheim
- 8.5.1 Boehringer Ingelheim Company Information
- 8.5.2 Boehringer Ingelheim Business Overview
- 8.5.3 Boehringer Ingelheim Equine Rhinopneumonitis Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Boehringer Ingelheim Equine Rhinopneumonitis Vaccine Product Portfolio
- 8.5.5 Boehringer Ingelheim Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Equine Rhinopneumonitis Vaccine Value Chain Analysis
- 9.1.1 Equine Rhinopneumonitis Vaccine Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Equine Rhinopneumonitis Vaccine Production Mode & Process
- 9.2 Equine Rhinopneumonitis Vaccine Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Equine Rhinopneumonitis Vaccine Distributors
- 9.2.3 Equine Rhinopneumonitis Vaccine Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst